Puretech Health (PRTC) Receives Buy Rating from Peel Hunt
Peel Hunt reaffirmed their buy rating on shares of Puretech Health (LON:PRTC) in a research report sent to investors on Thursday. The brokerage currently has a GBX 313 ($4.40) price objective on the stock.
Several other equities research analysts have also weighed in on the stock. Liberum Capital reaffirmed a buy rating and issued a GBX 248 ($3.48) target price on shares of Puretech Health in a report on Thursday, November 30th. N+1 Singer reaffirmed a buy rating on shares of Puretech Health in a report on Thursday, November 30th. Jefferies Group reaffirmed a buy rating on shares of Puretech Health in a report on Friday, November 17th. Finally, Numis Securities reaffirmed a buy rating and issued a GBX 259 ($3.64) target price on shares of Puretech Health in a report on Monday, January 29th. Five research analysts have rated the stock with a buy rating, Puretech Health currently has a consensus rating of Buy and an average target price of GBX 260.20 ($3.65).
Shares of Puretech Health (PRTC) opened at GBX 175.50 ($2.46) on Thursday. Puretech Health has a fifty-two week low of GBX 110 ($1.54) and a fifty-two week high of GBX 183.50 ($2.58). The firm has a market cap of $416.69 and a PE ratio of -975.00.
About Puretech Health
PureTech Health plc is a cross-disciplinary healthcare company. The Company operates through two segments: growth stage businesses and project phase businesses. Businesses in the growth stage businesses segment are those whose activities focus on developing products to solve healthcare problems in varied markets.
Receive News & Ratings for Puretech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puretech Health and related companies with MarketBeat.com's FREE daily email newsletter.